Certara stock rises after $135 million divestiture to Veristat as analysts weigh MIDD focus and improving biopharma demand.
Latest Ratings for CERT
DateFirmActionFromTo Mar 2022Morgan StanleyMaintainsEqual-Weight Mar 2022BarclaysMaintainsOverweight Jan 2022JefferiesUpgradesHoldBuy
Importance Rank:
2